reports
Coloplast A/S - Selskabsmeddelelse nr. 02/2024 - Regnskabsmeddelelse, ...
Coloplast A/S - Selskabsmeddelelse nr. 02/2024 - Regnskabsmeddelelse, 1. halvår 2023/24 H1 2023/24Regnskabsmeddelelse, 1. halvår 2023/241. oktober 2023 – 31. marts 2024 Coloplast leverede et solidt 2. kvartal med 8% organisk vækst og en overskudsgrad1) på 27%. Den rapporterede omsætning målt i danske kroner steg 9% med 4 procentpoint bidrag fra Kerecis (underliggende vækst på ca. 35%), delvist udlignet af valutaer. Den organiske vækst pr. forretningsområde var 7% i Stomi, 8% i Kontinens, 13% i Stemme og Respiratorisk Pleje, 8% i Avanceret Sårpleje (8% i Avancerede Sårbandag...
Coloplast A/S - Announcement no. 02/2024 - Interim Financial Report, H...
Coloplast A/S - Announcement no. 02/2024 - Interim Financial Report, H1 2023/24 H1 2023/24Interim financial results, H1 2023/241 October 2023 - 31 March 2024 Coloplast delivered a solid Q2 with 8% organic growth and an EBIT margin1) of 27%. Reported revenue in DKK grew 9% with 4%-points contribution from Kerecis (underlying growth of around 35%), partly offset by currencies. Organic growth rates by business area: Ostomy Care 7%, Continence Care 8%, Voice and Respiratory Care 13%, Advanced Wound Care 8% (Advanced Wound Dressings 8%) and Interventional Urology 5%.Continu...
TFS Financial Corp: 1 director
A director at TFS Financial Corp sold 13,400 shares at 13.140USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
HCA Healthcare Inc: 1 director
A director at HCA Healthcare Inc sold 1,863 shares at 312.000USD and the significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
PWR Holdings Limited: 1 director
A director at PWR Holdings Limited maiden bought 10,000 shares at 11.950AUD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
- ABGSC Capital Goods Research
- Anders Idborg
- Karl Bokvist
- Olof Cederholm
- ABGSC Healthcare Research
- Morten Larsen
Galderma Receives Filing Acceptances for Nemolizumab in Prurigo Nodula...
ZUG, Switzerland--(BUSINESS WIRE)-- Galderma today announced that it has received filing acceptances for nemolizumab for the treatment of patients with prurigo nodularis and for adolescents and adults with moderate-to-severe atopic dermatitis in Australia, Singapore, Switzerland, and the United Kingdom, whose regulatory authorities are members of the Access Consortium. An approval decision is expected from the consortium next year. Nemolizumab is a therapy specifically inhibiting IL-31 signaling to provide safe and rapid relief from the most burdensome symptom of both skin conditions: itch.1-7...
Aspo Group Interim Report, January 1 – March 31, 2024: Successful stra...
Aspo Group Interim Report, January 1 – March 31, 2024: Successful strategy execution in a challenging operating environment Aspo Plc Interim Report May 7, 2024, at 8:00 amAspo Group Interim Report, January 1 – March 31, 2024 Successful strategy execution in a challenging operating environment Figures from the corresponding period in 2023 are presented in brackets. January–March 2024 Net sales from continuing operations decreased to EUR 132.7 (141.6) million.Comparable operating profit from continuing operations was EUR 4.8 (8.4) million, 3.6% (5.9%) of net sales. The com...
Eezy Plc's Interim Report 1–3/2024: Demand for staffing services remai...
Eezy Plc's Interim Report 1–3/2024: Demand for staffing services remains weak – focus on increasing productivity EEZY PLC -- INTERIM REPORT -- 7 MAY 2024 AT 8:00 Eezy Plc's Interim Report 1–3/2024: Demand for staffing services remains weak – focus on increasing productivity January–March 2024 Revenue was EUR 41.5 million (EUR 52.8 million in January–March 2023). Revenue decreased by 21%.EBITDA was EUR 2.3 million (3.4).EBIT was EUR 0.5 million (1.3) and was 1.2% of revenue (2.5%).EUR 0.3 million in personnel expenses related to severance payments were recorded in the result.Earnings ...
Innate Pharma organise une conférence téléphonique pour présenter ses ...
MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») a annoncé aujourd'hui qu'elle organisera une conférence téléphonique le mardi 14 mai 2024 à 14H00 CEST / 8h00 EDT afin de présenter ses résultats financiers et l’avancée de son portefeuille au premier trimestre 2024. La conférence sera animée par : Hervé Brailly, Président du Directoire Sonia Quaratino, Vice-président exécutif, Directeur Médical Yannis Morel, Vice-président exécutif, Directeur des Opérations Frédéric Lombard, Vice-présiden...
argenx to Present at BofA Securities 2024 Health Care Conference
argenx to Present at BofA Securities 2024 Health Care Conference May 7, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in a fireside chat at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024 at 10:00 AM PT in Las Vegas, NV. A live webcast of the fireside chat may be accessed on the Investors section of the argenx website at . A replay of the webcast will be availabl...
Aspo-konsernin osavuosikatsaus 1.1.–31.3.2024: Vahvaa strategian toteu...
Aspo-konsernin osavuosikatsaus 1.1.–31.3.2024: Vahvaa strategian toteutusta haastavassa toimintaympäristössä Aspo Oyj Osavuosikatsaus 7.5.2024 klo 8.00Aspo-konsernin osavuosikatsaus 1.1.–31.3.2024 Vahvaa strategian toteutusta haastavassa toimintaympäristössä Suluissa on esitetty vuoden 2023 vastaavan ajanjakson luvut. Tammi–maaliskuu 2024 Liikevaihto jatkuvista toiminnoista laski ja oli 132,7 Me (141,6).Vertailukelpoinen jatkuvien toimintojen liikevoitto oli 4,8 Me (8,4) eli 3,6 % (5,9) liikevaihdosta. ESL Shippingin vertailukelpoinen liikevoitto oli 2,7 Me (6,0), Telkon 2,2 Me (2,7) j...
Eezy Oyj:n osavuosikatsaus 1–3/2024: Henkilöstöpalveluiden kysyntä ede...
Eezy Oyj:n osavuosikatsaus 1–3/2024: Henkilöstöpalveluiden kysyntä edelleen vaimeaa – katse tuottavuuden nostamisessa EEZY OYJ -- OSAVUOSIKATSAUS -- 7.5.2024 KLO 8.00 Eezy Oyj:n osavuosikatsaus 1–3/2024: Henkilöstöpalveluiden kysyntä edelleen vaimeaa – katse tuottavuuden nostamisessa Tammi–maaliskuu 2024 Liikevaihto oli 41,5 milj. euroa (52,8 milj. euroa tammi–maaliskuussa 2023). Liikevaihto laski 21 %.Käyttökate oli 2,3 milj. euroa (3,4).Liikevoitto oli 0,5 milj. euroa (1,3) ja oli 1,2 % liikevaihdosta (2,5 %).Tulokseen sisältyy työsuhteiden päättymisiin liittyviä henkilöstökuluja 0,3...
25/2024・Trifork Group AG – Interim report for the quarter ending 31 Ma...
25/2024・Trifork Group AG – Interim report for the quarter ending 31 March 2024 Trifork Group – Interim report for the quarter ending 31 March 2024Company announcement no. 25 / 2024Schindellegi, Switzerland – 7 May 2024Trifork Group reports Q1 revenue growth of 1.4% impacted by fewer working daysFirst quarter 2024 Trifork Group In Q1 2024, Trifork Group revenue amounted to EURm 50.4, an increase of 1.4% from Q1 2023. The quarter was impacted by fewer business days in the quarter due to the Easter break being in March instead of April as in the past years. The effect of this is es...
Sandoz reports first quarter 2024 sales
Sandoz reports first quarter 2024 sales Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong first quarter performance, with net sales [1] of USD 2.5 billion, up 6% in constant currencies (up 5% in USD)Biosimilar business growing 21% in constant currencies All regions contributing to growthAcquisition of CIMERLI® (ranibizumab-eqrn) completed in March 2024 Basel, May 7, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced net sales for the first quarter 2024. Net sales wer...
Fingerprint Cards AB (publ) publishes interim report for January – Mar...
Fingerprint Cards AB (publ) publishes interim report for January – March 2024 Highlights Q1 2024 Positive momentum in PC continued, with an 80-percent year-on-year growthSlight increase in gross margin compared to the previous quarter, as profitability in non-Mobile areas continues to be strongContinued execution of cost optimization program, with a nine-percent reduction in the number of employees since the end of 2023 Post-Q1 2024 By winding down the loss-making operations in Mobile, we will have a focused and profitable growth businessAnnounced partially guaranteed rights issue ...
KH Group Plc’s Business Review January–March2024: Focus on business pr...
KH Group Plc’s Business Review January–March2024: Focus on business profitability KH Group Plc Stock Exchange Release 7 May 2024 at 8.00 am EEST KH Group Plc’s Business Review January–March 2024: Focus on business profitability This is the summary of the Business Review for January–March 2024. The full Half-Year Report is attached to this release and is also available on the company’s website at . KH Group, January–March 2024 pro forma Net sales amounted to EUR 84.2 (100.2) million.Operating profit was EUR -0.3 (1.0) million.KH-Koneet’s net sales and operating profit de...
KH Group Oyj:n liiketoimintakatsaus tammi–maaliskuu 2024: Fokus liiket...
KH Group Oyj:n liiketoimintakatsaus tammi–maaliskuu 2024: Fokus liiketoiminnan kannattavuudessa KH Group Oyj Pörssitiedote 7.5.2024 klo 8.00 KH Group Oyj:n liiketoimintakatsaus tammi–maaliskuu 2024: Fokus liiketoiminnan kannattavuudessa Tämä on tiivistelmä vuoden 2024 tammi-maaliskuun liiketoimintakatsauksesta. Katsaus on kokonaisuudessaan tämän tiedotteen liitteenä sekä saatavissa yhtiön verkkosivuilla osoitteessa . KH Group konserni Tammi–maaliskuu 2024 pro forma Liikevaihto oli 84,2 (100,2) milj. euroa.Liikevoitto oli -0,3 (1,0) milj. euroa....
TGS Launches Multi-Client Wind and Metocean Measurement Campaign Offsh...
TGS Launches Multi-Client Wind and Metocean Measurement Campaign Offshore Germany OSLO, Norway (07 May 2024) – TGS, a global provider of energy data and intelligence, has today announced the commencement of its latest multi-client wind measurement campaign using two LiDAR buoys offshore Germany in the North Sea. The buoys are equipped with a multitude of sensors, allowing detailed measurements of wind, metocean and environmental data. The collected data is streamed to shore and used to enhance decision-making to support several current and future wind lease rounds in the German Bight...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.